The extension granted by Nasdaq provides Virax Biolabs Group with more time to improve its stock price and meet the minimum bid price requirement. This could potentially lead to increased investor confidence as it reduces the immediate risk of delisting. However, the company still needs to meet the requirement within the extended period to maintain its listing status.